Skip to content
RDL Network logo
Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma — Michael S. Khodadoust (2020) | RDL Network